Publications by authors named "L Perry Brothers"
Background: Bleeding events after arterial transcatheter procedures are associated with increased morbidity and mortality. The frequency and clinical implications of bleeding after mitral transcatheter edge-to-edge repair (M-TEER) have not been well-studied.
Objectives: The authors sought to explore the association of in-hospital bleeding events after M-TEER with patient outcomes.
Article Synopsis
- The study investigates the use of cangrelor in patients with myocardial infarction (MI) who also have cardiogenic shock (CS), focusing on the infusion duration and transition to oral medications.
- A total of 249 patients with CS were analyzed, with significant observations on demographics, infusion times, and the occurrence of major adverse cardiovascular events (MACEs) and bleeding risks.
- The findings showed that patients with CS had longer cangrelor infusions compared to others, and that the use of mechanical circulatory support (MCS) was linked to longer infusion times and an increased risk of bleeding.
Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2Y Inhibitor Therapy: The CAMEO Registry.
J Soc Cardiovasc Angiogr Interv
February 2024
Article Synopsis
- The study investigated the bleeding risk associated with cangrelor in patients with myocardial infarction (MI) who had previously taken an oral P2Y inhibitor before angiography.
- The CAMEO registry analyzed 1802 patients treated with cangrelor, finding that 21.4% had also received an oral P2Y inhibitor within the previous 24 hours.
- Results showed no significant difference in bleeding rates between patients with and without prior oral P2Y inhibitor exposure, indicating that cangrelor use does not substantially increase bleeding risk in either group.
Article Synopsis
- - The study focused on Mitral valve transcatheter edge-to-edge repair (MTEER) for functional mitral regurgitation (FMR), evaluating patients not included in the COAPT trial, analyzing outcomes through the Transcatheter Valve Therapy Registry data from 2013 to 2020.
- - Out of 6,675 patients, 55.7% were eligible and 44.3% were ineligible for the trial, with ineligible patients experiencing lower procedural success and more in-hospital complications but similar health status improvements at 30 days post-procedure.
- - However, trial-ineligible patients had a significantly higher risk of death or hospitalization due to heart failure within a year, highlighting differences in
Purpose Of Review: Despite advances in treatment, chronic graft-versus-host disease (cGVHD) remains a highly morbid complication of allogeneic hematopoietic stem cell transplantation. Due to direct effects of the disease on specific body sites, and its treatment, patients lose function. This review summarizes the latest evidence surrounding how cGVHD affects function, and restorative interventions.
View Article and Find Full Text PDF